CIPO Patents = 3 (Patent Applications = 1)

EPO Patents = 6 (Patent Applications = 2)

Average Co-Inventor Count = 9.6

ph-index = 5

Forward Citations = 74(Granted Patents)

Location History:

Chiba, JP (1997 - 2000)
Abiko, JP (2007 - 2012)
Tsukuba, JP (2008 - 2022)

Company Filing History:

7 out of 677

Eisai Company, Limited

patents

6 out of 527

Eisai R&d Management Co., Ltd.

patents

Years Active: 1997-2022

Loading Chart...

13 patents (USPTO):Sort by Forward Citations

Abstract keywords

1. 11479552 - Substituted piperidine compounds and their use (2022-10-25),

2. 9738656 - Pyranodipyridine compound (2017-08-22),

3. 8329742 - Macrocyclic compounds useful as pharmaceuticals (2012-12-11),

4. 7915306 - Macrocyclic compounds useful as pharmaceuticals (2011-03-29),

5. 7910734 - Crystal and salt of 1-cyclopropylmethyl-4-[2-(3,3,5,5-tetramethylcyclohexyl)phenyl]piperazine (2011-03-22),

6. 7799827 - Macrocyclic compounds useful as pharmaceuticals (2010-09-21),

7. 7425554 - 1,2-di(cyclic)substituted benzene compounds (2008-09-16),

8. 7410971 - 1,2-di(cyclic)substituted benzene compounds (2008-08-12),

9. 7304083 - 2-iminoimidazole derivatives (2) (2007-12-04),

10. 7244730 - 2-iminopyrrolidine derivatives (2007-07-17),

11. 6051705 - Substituted thiazolo[3,2-a]azepine derivatives (2000-04-18),

12. 5789403 - Substituted thiazolo �3,2-a!azepine derivatives (1998-08-04),

13. 5679671 - Amino acid derivative (1997-10-21),

Title: Innovator Makoto Kotake: A Leader in Pharmaceutical Patents

Introduction

Makoto Kotake, located in Tsukuba, Japan, is a distinguished inventor with a remarkable portfolio of 13 patents. His contributions primarily focus on pharmaceuticals, specifically in the development of compounds that offer therapeutic benefits.

Latest Patents

Among his recent innovations, Kotake has introduced substituted piperidine compounds, which are known for their orexin type 2 receptor-activating activity. The patents detail various compounds represented by formulas (I), (II), (III), and (IV), along with their pharmaceutically acceptable salts. Additionally, he has developed pyranodipyridine compounds, which are described in his work through formulas (I) to (XXII) and also as pharmaceutically acceptable salts.

Career Highlights

Throughout his career, Kotake has made significant advancements while working at Eisai Company, Limited and Eisai R&D Management Co., Ltd. His role in these reputable organizations underscores his commitment to innovation in the pharmaceutical sector.

Collaborations

Makoto Kotake has collaborated with esteemed colleagues, including Naoki Yoneda and Toshiyuki Matsuoka. These partnerships have facilitated the exploration and development of advanced compounds and have contributed to his ongoing success as an inventor.

Conclusion

In summary, Makoto Kotake’s extensive work and innovative patents within the pharmaceutical industry exemplify his dedication to improving human health through scientific advancement. His collaborations and career choices reflect a strong commitment to research and development, making him a leading figure in his field.

This text is generated by artificial intelligence and may not be accurate.